scholarly journals Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices

Eye ◽  
2009 ◽  
Vol 24 (5) ◽  
pp. 775-783 ◽  
Author(s):  
C Cukras ◽  
Y D Wang ◽  
C B Meyerle ◽  
F Forooghian ◽  
E Y Chew ◽  
...  
Keyword(s):  
Decision Making ◽  
Optical Coherence Tomography ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Spectral Domain ◽  
Optical Coherence ◽  
Age Related

scholarly journals Assessing Dry Age-Related Macular Degeneration in a Mexican Population with Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography

2018 ◽  
Vol 09 (05) ◽  
Author(s):  
Renata del Carmen Garcia Franco ◽  
Marlon Rafael Garcia Roa ◽  
Veronica Romero Morales ◽  
Miguel Angel Vazquez Membrillo ◽  
Ximena Mira Lorenzo ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Macular Degeneration ◽  
Fundus Autofluorescence ◽  
Mexican Population ◽  
Age Related Macular Degeneration ◽  
Spectral Domain ◽  
Optical Coherence ◽  
Age Related

scholarly journals Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Georges Azar ◽  
Benjamin Wolff ◽  
Flore De Bats ◽  
Jeremie Halfon ◽  
Mate Streho ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Macular Degeneration ◽  
Morphological Features ◽  
Age Related Macular Degeneration ◽  
Spectral Domain ◽  
Prognostic Indicators ◽  
Optical Coherence ◽  
Multicentric Study ◽  
Age Related ◽  
Sd Oct

Purpose. To identify spectral-domain optical coherence tomography (SD-OCT) predictive morphological features for the outcome of Ranibizumab therapy for neovascular age-related macular degeneration (AMD). Methods. This is a retrospective multicentric study that involved 64 eyes with naïve AMD. Patients who received three monthly intravitreal injections of Ranibizumab were stratified into (1) “responders” [≥ 5 letters gain on Early Treatment Diabetic Retinopathy Study (ETDRS) scale] and (2) “nonresponders” (< 5 letters gain). Best-corrected visual acuity (BCVA) and SD-OCT morphological features were compared at baseline and one month after three consecutive injections of Ranibizumab. Univariate and multivariate analyses were carried out to correlate these morphological features with the change in BCVA. Results. Among the 64 patients enrolled, 40 (62.5%) were “responders” and 24 (37.5%) “nonresponders”. Age, sex, and BCVA were comparable between both groups. A multivariate correlational analysis found that subfoveal choroidal thickness (SFCT) and the presence of pigment epithelial detachment (PED) > 250 μm at baseline were two independent prognostic indicators of final BCVA. No other SD-OCT morphological studied features seem to affect final BCVA after Ranibizumab treatment. Conclusion. SFCT and the presence of PED > 250 μm are two significant biomarkers that may predict improvement after Ranibizumab therapy for AMD. These markers may guide ophthalmologists' treatment decision under financial constraints and limited time.

Sign in / Sign up

Export Citation Format

Share Document